Table 1 |
||
|
Clinicopathological characteristics of patients, primary breast tumours, and treatment |
||
| Number of patients (percentage) |
||
|
|
||
| Total number of patients |
73 |
|
| Age at diagnosis (years) |
≤50 >50 |
34 (46.6) 39 (53.4) |
| Range |
29 to 77 |
|
| Tumour size (cm) |
<2.0 ≥2.0 |
20 (27.4) 53 (72.6) |
| Number of positive lymph nodes |
0 1–3 >3 |
21 (28.8) 20 (27.4) 32 (43.8) |
| Histological grade |
1 2 3 |
12 (16.4) 42 (57.5) 19 (26.1) |
| Adjuvant therapy |
None Endocrine therapy Chemotherapy Combined |
5 (6.9) 32 (43.8) 2 (2.7) 34 (46.6) |
| Disease-free interval (months) |
Mean ± SD Median |
39.8 ± 25.7 38 |
| Range |
2 to 123 |
|
| First-line endocrine therapy for metastatic breast cancer |
Tamoxifen Aromatase inhibitors LHRH agonist LHRH agonist + tamoxifen Fulvestrant |
56 (76.7) 9 (12.3) 3 (4.1) 4 (5.5) 1 (1.4) |
|
|
||
|
LHRH, luteinising hormone-releasing hormone; SD, standard deviation. |
||
|
Yamashita et al. Breast Cancer Research 2006 8:R48 doi:10.1186/bcr1536 |
||
